Literature DB >> 6418251

Effects of drugs on the cerebral circulation of the dog in relation to the cerebral oxygen consumption.

W P Chin, S Imai, U Nakano, K Takeda, H Tamatsu, T Ushijima.   

Abstract

Drug effects were studied on the cerebral circulation by measuring the sagittal sinus outflow in the anaesthetized dog following the method of Michenfelder and by monitoring cerebral oxygen consumption. Systemic aortic pressure, heart rate and spinal fluid pressure were also studied. Since dilatation of cerebral vessels was observed in nearly all the preparations after inhalation of CO2, it was thought that gross extracerebral contamination was virtually eliminated in this preparation. A close correlation was observed between the oxygen consumption of the brain as a whole and the sagittal sinus outflow (r = 0.93, P less than 0.001); therefore it became feasible to differentiate the direct effects of drugs on cerebral blood vessels from indirect ones attributable to changes in the cerebral oxidative metabolism. Sodium pentobarbitone (5 mg kg-1, i.v.), reduced the cerebral venous outflow and caused a decrease in the oxygen consumption. Pentylenetetrazol (30 mg kg-1 i.v.) and bemegride (5 mg kg-1 i.v.) produced an increase in the blood flow and a corresponding increase in the cerebral oxygen consumption. Thus, it was concluded these substances had no direct effects on the cerebral blood vessels. Acetazolamide (10 mg kg-1, i.v.), a carbonic anhydrase inhibitor, produced a marked and sustained vasodilatation after a latent period of 0.5-1 min. There was no increase in the cerebral oxygen consumption. A similar pattern was seen after CO2 had been inhaled. Methylergometrine and dihydroergotamine (20 micrograms kg-1 i.v.) induced a prolonged vasoconstriction of the cerebral vascular bed without any changes in the oxygen consumption of the brain. Therefore this method can discriminate between indirect or direct effects of drugs on cerebral vascular outflow.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418251      PMCID: PMC2044948          DOI: 10.1111/j.1476-5381.1983.tb10534.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  [Influence of barbiturate antagonist analeptics on EEG, oxygen uptake and blood flow of brain in severe veronal poisoning of dogs].

Authors:  H DAWEKE; F HAHN; A OBERDORF
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1959

2.  CUTANEOUS BLOOD FLOW IN VASCULAR HEADACHES OF THE MIGRAINE TYPE.

Authors:  A H ELKIND; A P FRIEDMAN; J GROSSMAN
Journal:  Neurology       Date:  1964-01       Impact factor: 9.910

3.  Sulfur-35 labeled acetazolamide in cat brain.

Authors:  L J ROTH; J C SCHOOLAR; C F BARLOW
Journal:  J Pharmacol Exp Ther       Date:  1959-02       Impact factor: 4.030

4.  The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog.

Authors:  A CARPI; M VIRNO
Journal:  Br J Pharmacol Chemother       Date:  1957-06

5.  Pharmacological study on electrical activity and oxygen consumption of brain cortex.

Authors:  N FUJITA
Journal:  Jpn J Pharmacol       Date:  1956-03

6.  Effects of barbiturate sedation on the brain in toxemia of pregnancy.

Authors:  M L McCALL; H W TAYLOR
Journal:  J Am Med Assoc       Date:  1952-05-03

Review 7.  Local chemical and neurogenic regulation of cerebral vascular resistance.

Authors:  W Kuschinsky; M Wahl
Journal:  Physiol Rev       Date:  1978-07       Impact factor: 37.312

8.  Cerebral and renal vascular smooth muscle responses to adenosine.

Authors:  J P Buyniski; C E Rapela
Journal:  Am J Physiol       Date:  1969-12

9.  Simultaneous cerebral blood flow measured by direct and indirect methods.

Authors:  J D Michenfelder; J M Messick; R A Theye
Journal:  J Surg Res       Date:  1968-10       Impact factor: 2.192

10.  The role of adenosine in the regulation of cerebral blood flow.

Authors:  H R Winn; G R Rubio; R M Berne
Journal:  J Cereb Blood Flow Metab       Date:  1981       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.